Prostate cancer symptoms: Notice this change in your body? It may signify the cancer has a

PROSTATE cancer is the most common cancer in men in the UK. Spotting the warning signs significantly improves a person ’s outcome. If the cancer has spread, symptoms can show up in different parts of the body. One sign of advanced cancer can have a profound impact on a person’s day to day life.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 20 October 2019Source: European UrologyAuthor(s): Melissa A. Reimers, Steven M. Yip, Li Zhang, Marcin Cieslik, Mallika Dhawan, Bruce Montgomery, Alexander W. Wyatt, Kim N. Chi, Eric J. Small, Arul M. Chinnaiyan, Ajjai S. Alva, Felix Y. Feng, Jonathan ChouAbstractBackgroundCyclin-dependent kinase 12 (CDK12) loss occurs in 3–7% of metastatic prostate cancer patients and is characterized by a genomic instability signature, but the clinical implications of CDK12 loss are not well established.ObjectiveTo determine the clinical course of patients with CDK12 mutant advanced prostate cancer...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Abstract The UK National Institute for Health and Care Excellence (NICE) 2019 "Prostate cancer: diagnosis and management" guidelines have recommended that all patients suspected of prostate cancer undergo multiparametric magnetic resonance imaging (mpMRI) prior to biopsy. The Likert scoring system is advocated for mpMRI reporting based on multicentre studies that have demonstrated its effectiveness within the National Health Service (NHS). In recent years, there has been considerable drive towards standardised prostate reporting, which led to the development of "Prostate Imaging-Reporting And Data S...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Radiol Source Type: research
Abstract The diagnosis of prostate cancer has changed. Improved magnetic resonance imaging (MRI) technology with diffusion-weighted imaging has led to the use of multiparametric MRI (mpMRI) before biopsy in patients suspected of having prostate cancer. This has the advantage that patients with a negative mpMRI may not need biopsy, therefore avoiding the risk of complications. Those in whom mpMRI is positive can have targeted biopsies with a higher probability of diagnosing clinically significant cancer. Prostate Cancer UK (PCUK) and the British Society of Urogenital Radiology submitted a Freedom of Information (FO...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Radiol Source Type: research
ConclusionsDifferential disease classification among men who may be recommended to undergo and then consider whether to accept a prostate biopsy leads to inaccurate identification of prostate cancer risk factors. Imputing a man’s prostate cancer status reduces detection bias. Covariate adjustment does not address the problem of outcome misclassification. Cohorts evaluating incident prostate cancer should collect longitudinal screening and biopsy data to adjust for this potential bias.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Radiolabelled PSMA imaging seems to be useful in analyzing glioma/glioblastoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of radiolabelled PSMA in this setting and its possible position in the diagnostic flow-chart. PMID: 31625482 [PubMed - as supplied by publisher]
Source: Current Radiopharmaceuticals - Category: Radiology Tags: Curr Radiopharm Source Type: research
In this study, LNCaP cells were exposed to FICZ, CH223191 and flutamide (Flu) alone or in combination in the presence and absence of testosterone. CYP1A1 enzyme activity, cell viability, cellular prostate-specific antigen (PSA) and dihydrotestosterone (DHT) production, mRNA levels of PSA, KLK2, TMPRSS2, and AR genes were measured as endpoints. A declining in the expression of androgen- responsive target genes was seen by either Flu or FICZ in the presence of testosterone. Furthermore, the forced decrease in the expression of AR target genes resulted in 41% and 31% decline in the DHT and PSA concentrations respectively. Tak...
Source: Steroids - Category: Drugs & Pharmacology Source Type: research
Authors: Yoshizawa T, Yamaguchi K, Kawata N, Ryuzaki H, Ogawa M, Obinata D, Mochida J, Takahashi S Abstract We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
The objective of this study was to identify favorable subgroups for alternative anti-androgen therapy among CRPC patients. Eighty-eight consecutive CRPC patients treated with alternative anti-androgen therapy were included in this study. All patients were treated with bicalutamide in the initial maximum androgen blockade (MAB) and switched to flutamide in the subsequent alternative anti-androgen therapy, combined with a luteinizing hormone-releasing hormone analogue. Several clinical and pathological factors for predicting the prostate-specific antigen (PSA) decline and PSA progression-free survival (PSA-PFS) of alternativ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Publication date: Available online 17 October 2019Source: Urology Case ReportsAuthor(s): Amer Amin, Alexandar Blazevski, Matthijs Scheltema, Phillip StrickerAbstractA 75-year-old man with a background history of total colectomy (including the distal rectum anal canal), has a suspicion of prostate cancer based on an elevated PSA and high risk features on multiparametric MRI. Here we describe the case in detail including the technique utilized to obtain prostate biopsy cores.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: Available online 17 October 2019Source: European UrologyAuthor(s): Wei Phin Tan, Thomas J. Polascik
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Health | Prostate Cancer | Warnings